Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated July 25, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on July 24, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics
- Shares Purchased (July 24, 2025): 491,631 ordinary shares.
- Price Range: Lowest price paid was 1,374.00 GBp; highest price paid was 1,403.00 GBp.
- Volume-Weighted Average Price: 1,393.28 GBp.
- Program Progress: Since June 4, 2025, the Company has purchased a total of 16,677,357 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 234,811,740 ordinary shares in treasury.
- Shares in Issue: 4,080,572,540 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.75% of the total voting rights.
Material Changes
The filing does not report material changes to revenue, profit, or operational metrics. The primary change is the reduction of shares in issue and the increase in treasury stock resulting from the buyback program. The filing confirms the ongoing execution of the share repurchase program announced in June 2025.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of risks and contingencies. It is a routine disclosure of a share transaction. The purchased shares are held as Treasury shares.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback program since June 4, 2025 (16,677,357).
- Confirm the current percentage of voting rights held in treasury (5.75%) against regulatory thresholds.
- Review the volume-weighted average price (1,393.28 GBp) relative to the market price on the transaction date.
- Check the remaining authorization or limit of the existing buyback program, as the filing does not specify the total program size.